Remission induction, consolidation, early continuation, reinduction therapy, and continuation A and B
| Agent . | Dosage . | Route and schedule . |
|---|---|---|
| Remission induction (4 wk) | ||
| Prednisone | 40 mg/m2/d | Orally d 1-28 |
| Vincristine | 1.5 mg/m2/wk | IV d 5, 12, 19, 26 |
| Daunomycin | 25 mg/m2/wk | IV d 5, 12 |
| L-asparaginase (Escherichia coli) | 10 000 U/m2 thrice weekly | IM d 6, 8, 10, 12, 14, 16 |
| Triple intrathecal | Age dependent1 | IT d 5, (12),* 19 |
| Consolidation (8 wk) | ||
| HD-MTX | 2.5 g/m2, 4-h infusion | IV d 1, 15, 29, 43 |
| Mercaptopurine | 50 mg/m2/d | IV d 1-56 |
| Triple intrathecal | Age dependent1 | IT d 1, 15, 29, 43 |
| Early continuation (6 wk) | ||
| Dexamethasone | 6 mg/m2/d | Orally d 1-7 |
| Vincristine | 2 mg/m2 | IV d 1 |
| Mercaptopurine | 75 mg/m2/d | Orally d 8-42 |
| MTX | 40 mg/m2/wk | IV/IM d 8, 15, 22, 29, 36 |
| Triple intrathecal | Age dependent1 | IT d 15 |
| Reinduction (6 wk) | ||
| Dexamethasone | 6 mg/m2/d | Orally d 1-7, 15-21 |
| Vincristine | 1.5 mg/m2/wk | IV d 1, 8, 15, 22 |
| L-asparaginase (E coli) | 25 000 U/m2/wk | IM d 1, 8, 15, 22 |
| HD-MTX | 2.5 g/m2, 4-h infusion | IV d 29 |
| Mercaptopurine | 50 mg/m2/d | Orally d 29-42 |
| Triple intrathecal | Age dependent1 | IT d 1, 29 |
| Continuation A (40 wk) | ||
| Mercaptopurine | 75 mg/m2/d × 7 d | Orally wk 25-64 |
| MTX | 40 mg/m2/wk | IV/IM wk 25, 26, 28-30, 32-34, 36-38, 40-42, 44-46, 48-50, 52-54, 56-58, 60-63 |
| Vincristine | 1.5 mg/m2/wk | IV wk 27, 31, 35, 39, 43, 47, 51, 55 |
| Dexamethasone | 6 mg/m2/d × 5 d | Orally wk 27, 31, 35, 39, 43, 47, 51, 55, 59, 64 |
| Triple intrathecal | Age dependent1 | IT wk 27, 35, 43, 51, 59, 64 |
| Continuation B (52 wk) | ||
| Mercaptopurine | 75 mg/m2/d × 7 d | Orally wk 65-116 |
| MTX | 40 mg/m2 | IV/IM wk 65-116 |
| Triple intrathecal | Age dependent1 | IT wk (72, 80, 88, 96, 104, 112)* |
| Agent . | Dosage . | Route and schedule . |
|---|---|---|
| Remission induction (4 wk) | ||
| Prednisone | 40 mg/m2/d | Orally d 1-28 |
| Vincristine | 1.5 mg/m2/wk | IV d 5, 12, 19, 26 |
| Daunomycin | 25 mg/m2/wk | IV d 5, 12 |
| L-asparaginase (Escherichia coli) | 10 000 U/m2 thrice weekly | IM d 6, 8, 10, 12, 14, 16 |
| Triple intrathecal | Age dependent1 | IT d 5, (12),* 19 |
| Consolidation (8 wk) | ||
| HD-MTX | 2.5 g/m2, 4-h infusion | IV d 1, 15, 29, 43 |
| Mercaptopurine | 50 mg/m2/d | IV d 1-56 |
| Triple intrathecal | Age dependent1 | IT d 1, 15, 29, 43 |
| Early continuation (6 wk) | ||
| Dexamethasone | 6 mg/m2/d | Orally d 1-7 |
| Vincristine | 2 mg/m2 | IV d 1 |
| Mercaptopurine | 75 mg/m2/d | Orally d 8-42 |
| MTX | 40 mg/m2/wk | IV/IM d 8, 15, 22, 29, 36 |
| Triple intrathecal | Age dependent1 | IT d 15 |
| Reinduction (6 wk) | ||
| Dexamethasone | 6 mg/m2/d | Orally d 1-7, 15-21 |
| Vincristine | 1.5 mg/m2/wk | IV d 1, 8, 15, 22 |
| L-asparaginase (E coli) | 25 000 U/m2/wk | IM d 1, 8, 15, 22 |
| HD-MTX | 2.5 g/m2, 4-h infusion | IV d 29 |
| Mercaptopurine | 50 mg/m2/d | Orally d 29-42 |
| Triple intrathecal | Age dependent1 | IT d 1, 29 |
| Continuation A (40 wk) | ||
| Mercaptopurine | 75 mg/m2/d × 7 d | Orally wk 25-64 |
| MTX | 40 mg/m2/wk | IV/IM wk 25, 26, 28-30, 32-34, 36-38, 40-42, 44-46, 48-50, 52-54, 56-58, 60-63 |
| Vincristine | 1.5 mg/m2/wk | IV wk 27, 31, 35, 39, 43, 47, 51, 55 |
| Dexamethasone | 6 mg/m2/d × 5 d | Orally wk 27, 31, 35, 39, 43, 47, 51, 55, 59, 64 |
| Triple intrathecal | Age dependent1 | IT wk 27, 35, 43, 51, 59, 64 |
| Continuation B (52 wk) | ||
| Mercaptopurine | 75 mg/m2/d × 7 d | Orally wk 65-116 |
| MTX | 40 mg/m2 | IV/IM wk 65-116 |
| Triple intrathecal | Age dependent1 | IT wk (72, 80, 88, 96, 104, 112)* |
IM, intramuscular; IT, intrathecal.
Patients with CNS status 2 or traumatic tap.